Delving into the Latest Updates on Finasteride with Synapse

Overview

Basic Info

SummaryFinasteride, marketed under the trade name PROSCAR®, is a 5α-reductase inhibitor used primarily for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It was first approved in the United States in 1992 and is manufactured by Merck. Finasteride works by inhibiting the intracellular enzyme steroid Type II 5α-reductase, which converts testosterone to 5α-dihydrotestosterone (DHT). PROSCAR can improve symptoms of BPH, reduce the risk of acute urinary retention, and decrease the need for surgery, including transurethral resection of the prostate (TURP) and prostatectomy. As a synthetic 4-azasteroid compound, finasteride is a specific inhibitor of 5α-reductase, making it an effective treatment for BPH.

Drug Type

Small molecule drug

Synonyms

(5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide, Finasteride (JAN/USP/INN), 非那雄胺（奎安）

+ [47]

Target

5α-reductase

Mechanism

5α-reductase inhibitors(Steroid 5 alpha reductase inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesUrogenital Diseases

Active Indication

Androgenetic AlopeciaAlopeciaProstatic Hyperplasia

Inactive Indication

Alopecia, Male PatternHematuriaHemospermia

Originator Organization

Merck & Co., Inc.

Active Organization

Kedi Biomedical (Wuxi) Co., Ltd.

Almirall Hermal GmbHCutia Therapeutics （HK） Limited

+ [4]

Inactive Organization

Polichem SA (Switzerland)

Nanjing Sanhome Pharmaceutical Co. Ltd.Merck Frosst Canada Ltd.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (19 Jun 1992),

Prostatic Hyperplasia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H36N2O2

InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N

CAS Registry98319-26-7

Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic "horseshoe" pattern. Incidence and prevalence of AGA depend on age and race.
Vichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.
The primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.

Start Date02 Nov 2024

Sponsor / Collaborator

Cosmetique Active International

[+2]

TCTR20240926001

/ Not yet recruitingPhase 3IIT

Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia

Start Date30 Sep 2024

Sponsor / Collaborator-

100 Clinical Results associated with Finasteride

Login to view more data

100 Translational Medicine associated with Finasteride

Login to view more data

100 Patents (Medical) associated with Finasteride

Login to view more data

3,175

Literatures (Medical) associated with Finasteride

01 Feb 2025·The Prostate

Does size matter? A single institution's comparison of Aquablation in prostates greater than or less than 150 mL

Article

Author: Horning, Paul ; Peters, Kenneth M. ; Gangwish, David ; Hafron, Jason ; Ringler, Renee ; Zwaans, Bernadette M. M. ; Kuperus, Joshua ; Palmateer, Greg

AbstractBackgroundSurgical management options for lower urinary tract symptoms due to benign prostatic hypertension have remained limited in prostates of large volume. The advent of the Aquablation has created a potential minimally invasive option for treatment in prostates of all volumes. Thus, this study aims to evaluate outcomes and complications of Aquablation in clinical practice based on prostate volume.MethodsCollected variables included adverse events with Clavien‐Dindo classifications, transfusion rates, surgical retreatment rates, continued medication use postoperatively, and International Prostate Symptom Score (IPSS) with Quality‐of‐Life indicator. Aquablations were stratified by preoperative prostate volume.ResultsOne hundred seventy‐four men were included in the study. The average postop decrease in IPSS was 10.28, with a 2.02 point decrease in Quality‐of‐Life at 1 year. Postop increase in peak urinary flow rate was 7.65 mL/s for an average of 16.44 mL/s. Hemoglobin drop average was 1.78 g/dL, but only 2.3% of patients required a transfusion. 12.9% of patients required surgical retreatment. Six months after Aquablation, 22.9% and 12.9% of patients continued taking Alpha‐blockers and Androgen receptor inhibitors, respectively. Adverse events occurred in 33 patients (19.0%). Eighteen patients were excluded from secondary analysis due to unrecorded prostate volume, leaving 123 with volumes <150 mL and 33 with volumes ≥150 mL. Groups were comparable with respect to length of stay, adverse events, blood transfusion, IPSS with Quality‐of‐Life indicator preoperative and postoperative, postop peak urinary flow, and postop alpha‐blocker use. Larger prostates had a higher rate of adverse events, retreatment, postop hemoglobin drop, and postop use of finasteride.ConclusionsAquablation is a viable treatment option for benign prostatic hyperplasia. Efficacy, safety, subjective outcomes, and adverse event rates were not impacted by prostate volume. However, size does matter as prostates ≥150 mL had higher surgical retreatment rates and postop finasteride use.

03 Jan 2025·Current Molecular Pharmacology

Doxazosin Attenuates Development of Testosterone Propionate-induced Prostate Growth by regulating TGF-β/Smad Signaling Pathway, Prostate-specific Antigen Expression and Reversing Epithelial-mesenchymal Transition in Mice and Stroma Cells

Article

Author: Shao, ZiChen ; Fu, ChenHao ; Li, YiDan ; Hua, JianQiang ; Mao, ChenYan ; Zhang, ZiWen ; Sun, Hui ; Zhang, Peng ; Wang, ZiTong ; Tu, BingHua ; Liu, Chi-Ming

Objectives:The present study examined the effects of doxazosin on testosterone propionate (TP)-induced prostate growth in vivo and in vitro and its impact on the EMT and TGF-β/Smad signaling pathway.Methods:Mice were treated with TP. Doxazosin (5 or 10 mg/kg) and finasteride (10 mg/kg) were administered orally for 28 days in TP-induced mice. The prostate index (prostate/body weight ratio), morphological characteristics and the protein expression of the prostate were examined. We further examined the effects of doxazosin and finasteride on the EMT and TGF-β/Smad signaling pathway in mice and in human prostate stroma cell (WPMY-1). The protein expressions of TGF-β1, TGFBR2, p-Smad2/3, N-cadherin, vimentin, fibronectin and α-SMA, E-cadherin and prostate specific antigen (PSA) were determined after treatment by western blot.Results:The prostate wet weight, prostate index decreased after treatment. Doxazosin (5 or 10 mg/kg), finasteride (10 mg/kg) or a combination treatment (doxazosin 10 mg/kg + finasteride 10 mg/kg) were shown to reverse the pathological and morphological characteristics of the prostate. Doxazosin and finasteride inhibited TP-induced prostate growth, EMT, and the TGF-β/Smad signaling pathway by downregulating the expression of TGF-β1, TGFBR2, p-Smad2/3, N-cadherin, vimentin, fibronectin and α-SMA, whereas expression of E-cadherin was increased after treatment with either doxazosin or finasteride. Doxazosin (1-50 μM) inhibited normal human prostate stroma cell growth (WPMY-1) after 48 h with or without testosterone treatment. Doxazosin also regulated the EMT and proteins related to the TGF-β/Smad signaling pathway in WPMY-1 cells after 24 h. Additionally, doxazosin decreased protein expression of the PSA both in vivo and in vitro.

01 Jan 2025·Journal of Medicinal Food

Evaluation of Hair Growth Promoting Activity of Standardized Soybean Extract on Testosterone-Induced Alopecia

Article

Author: Choucry, Mouchira A. ; Youssef, Alaa ; Al-Mahdy, Dalia A. ; Sayed, Rabab H. ; El-Askary, Hesham

Millions of men and women suffer from alopecia, especially androgenic alopecia (AGA), which is considered the most common form of hair loss. The available treatments for hair loss include multiple approaches, with the most popular being synthetic drugs including minoxidil and finasteride, in addition to natural products. However, synthetic drugs have shown many undesirable side effects, on the contrary, the specifications of the commonly used natural drugs have not been reported in most of the previous studies, despite the high market preference for them. One of these natural drugs is soybean (Glycine max), an economically important bean that has been reported in several studies to effectively prevent hair loss in humans and is widely used in many products treating alopecia. However, no reports were traced on the specification and standardization of the used soybean extract, which may lead to unreproducible results. Thus, in this study, we investigated the effects of different concentrations; 1%, 3%, and 5% (v/v) of a specified soybean extract (SSE) in coconut oil, using a testosterone-induced model of alopecia in adult male Wistar rats in comparison with a 2% finasteride solution. Visual and microscopical evaluations of follicular diameter, length, and density were performed. The data showed that 5% of SSE exhibited the highest activity with results comparable to standard 2% finasteride for hair diameter, length, and density, which could be attributed to the extract's isoflavone content. Genistin and diadzin isoflavones were isolated from the ethyl acetate fraction of the SSE. The total extract was standardized using high-performance liquid chromatography using genistin as a marker and showed a content of 6.2 µg/mL. Accordingly, the formulated 3% and 5% SSEs (containing 0.186 and 0.31 µg/mL of genistin, respectively) could be considered as a promising natural treatment for AGA.

91

News (Medical) associated with Finasteride

08 Jan 2025

·www.prnewswire.com

Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results

Demonstrates Potential for ET-02 to be Significantly More Effective Than Existing Treatments for Hair Loss WOBURN, Mass., Jan. 8, 2025 /PRNewswire/ -- Eirion Therapeutics Inc., a biopharmaceutical company focused on developing innovative aesthetic prescription product offerings, announced today the successful results of its first-in-man clinical trial for the treatment of androgenic alopecia (age-related hair loss) using its topical pharmaceutical ET-02. Jon Edelson, MD, CEO and President of Eirion, commented "80 million people in the United States suffer from hair loss and there is no truly effective treatment for this condition today. Because of ET-02's unique mechanism of action, we believe that ET-02 has the potential to not only treat but prevent androgenic alopecia. The results of this clinical trial show we are an important step closer to potentially having a solution for hair loss." In a double-blind, placebo-controlled, dose-ranging clinical study of 24 subjects at three U.S. investigational sites, three equal-sized groups were treated once daily for 4 weeks with either a control treatment comprised of the product vehicle, a 1.25% solution of ET-02 or a 5% solution of ET-02. A final assessment of the subjects was made one week after the treatments ended. Key results of the study showed: Safety: ET-02 was found to be safe and well tolerated. Dose-Response: A dose-response effect was observed, with minimal response observed in the vehicle and 1.25% ET-02 groups compared to the significant response observed in the higher dose 5% ET-02 group. Thus, for analysis, the placebo group was the combined vehicle and 1.25% ET-02 dose groups. Hair Growth: 5% ET-02 resulted in a 6-fold increase in non-vellus (or normal) hair count compared to the placebo group at the end of the fifth week of the study. For comparative purposes, after one month of treatment 5% ET-02 demonstrated more non-vellus hair growth than topical minoxidil produced after 4 months of treatment as measured in a separate clinical trial of minoxidil (N=180), the current "gold standard" treatment for androgenic alopecia. Hair Width: 5% ET-02 resulted in an approximately ten percentage point improvement in non-vellus hair width over the placebo group, which was essentially unchanged. Eirion's first-in-man study results confirm the efficacy of 5% ET-02 as demonstrated in a previous controlled pre-clinical study of topical 5% ET-02 treating 60 human scalp tissue grafts from men with androgenic alopecia. In that study, ET-02 was markedly more effective than the control group. The net rate of hair growth produced by ET-02 in the fourth month of treatment was four times greater than the amount produced by minoxidil in a second, separate pre-clinical study (N=103) using the same experimental graft model. Eirion plans to begin a Phase 2 clinical trial (N≈150) in 2025 with a 6-month treatment period with the goal of confirming ET-02's safety and efficacy. Jerry Shapiro, MD, a leading expert on the treatment of hair loss and Professor of Dermatology at New York University Grossman School of Medicine noted that "Eirion's clinical trial results are clear-cut and remarkable. Achieving this amount of hair growth in just 5 weeks in a clinical trial is unprecedented. ET-02 represents a potentially substantial advancement over minoxidil and other commercially available pharmaceuticals for patients struggling with hair loss, not only from an efficacy standpoint, but also from safety and ease-of-use standpoints. Due to its non-hormonal mechanism of action, ET-02 is not expected to have the same side effects that patients complain of, like sexual dysfunction, for androgen inhibition treatments like finasteride. ET-02 is being tested as a once-a-day treatment, rather than the less convenient twice-a-day regimen required for topical minoxidil." Dr Shapiro added, "I look forward to future clinical studies of ET-02." ET-02 has a novel mechanism of action which restores normal function to hair follicle stem cells that have become inactive in age-related hair loss due to a defect that develops in the stem cell biology. Hair follicle stem cells are known to be the "master control switches" for hair growth. By correcting this defect and returning the stem cells to normal activity and function, the expectation is that hair growth can be restored. Eirion expects ET-02 has the potential to be significantly more effective than existing treatments since it directly addresses what Eirion believes is the fundamental cause of androgenic alopecia, while existing treatments do not. Eirion also believes ET-02 has the potential to treat and prevent hair greying by impacting in a similar manner the melanocyte stem cells which control the production of hair color. Eirion Therapeutics will participate in the Aesthetics Tech Forum taking place January 9 – 10, 2025, in Newport Beach, California. Dr Edelson will present an update on Eirion and clinical trial results during the conference session "Company Presentations" that will take place on Thursday January 9th 1:25 PM – 2:30 PM PST. About Eirion Therapeutics, Inc. Eirion Therapeutics, Inc. is a privately held, clinical stage biopharmaceutical company that is developing next-generation prescription products for aesthetic medicine. Eirion currently has a rich pipeline of product candidates focusing on treatments for wrinkles, androgenic alopecia, hair greying and primary axillary hyperhidrosis. Eirion's product candidates, all of which have been studied in one or more clinical trials, include AI-09 liquid injectable neuromodulator, ET-01 topical neuromodulator, and ET-02 topical small molecule. To learn more about Eirion, please visit: Media Contact Megan Driscoll EvolveMKD [email protected] SOURCE Eirion Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2

12 Dec 2024

·www.globenewswire.com

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 indicating that the Company’s failure to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”) is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”). On December 10, 2024, the Company filed the Form 10-Q with the Securities and Exchange Commission. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. About Onconetix, Inc.: Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our recent acquisition of Proteomedix, we own Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union (“EU”) under the In Vitro Diagnostic Regulation (“IVDR”). We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia (“BPH”), a disorder of the prostate. For more information, visit www.onconetix.com. Contact Information: Onconetix, Inc.201 E. Fifth Street, Suite 1900Cincinnati, OH 45202Phone: (513) 620-4101 Investor Contact Information: Onconetix Investor RelationsEmail: investors@onconetix.com

AcquisitionDiagnostic Reagents

07 Oct 2024

·www.pharmaceutical-technology.com

EMA starts review into hair loss drugs about potential link to suicidal thoughts

Androgenic alopecia is a hair loss condition that primarily affects the top and front of the scalp. Credit: PippiLongstocking via Shutterstock. The European Medicines Agency (EMA) has started a review of popular anti-baldness and enlarged prostate medicines finasteride and dutasteride over concerns about their possible impact on causing suicidal thoughts. Finasteride is marketed as Propecia for male pattern hair loss (androgenetic alopecia) and Proscar for treating benign prostatic hyperplasia (BPH), by MSD’s spin-off company Organon. BPH is a condition in which the prostate is enlarged causing problems with the flow of urine. Dutasteride, which is marketed by GSK as Avodart, has a similar mechanism of action and is used to treat BPH. Avodart is also sometimes used off label for hair loss, with generic versions of finasteride and dutasteride available in the market. The safety review was requested by the French regulatory agency, the National Agency for the Safety of Medicines and Health Products, which said that all available data on suicidal ideation and suicide related to finasteride and dutasteride-containing products as well as the impact of these possible risks on the benefit-risk balance of these products should be reviewed. Finasteride and dutasteride are linked to psychiatric side effects according to French regulators. Suicidal ideation was recently added to the patient information sheets and packaging for both Propecia and Proscar in the EU. However, French authorities argue that the new safety reports alter the risk profile of finasteride. This was highlighted in the 4 October Article-31 referral document: “Even though a causal association between finasteride and suicidal ideation has not been established, it was considered at least a reasonable possibility, given that known ADRs [adverse drug reactions] such as sexual dysfunction/impotence, depression, decreased libido, may lead to suicidal ideation.” See Also: WuXi debates sale of pharma operations as BIOSECURE Act advances Ascendis Pharma submits sBLA for growth hormone deficiency therapy This is not the first time that questions have been raised about the psychiatric symptoms of these drugs. In June 2022, the US Food and Drug Administration (FDA) ordered a warning about suicidal thoughts and behaviour on the drug’s label but rejected a request to remove Propecia from the market. This followed a 2017 petition from a patient advocacy group called the Post-Finasteride Syndrome Foundation, which ordered MSD to either stop selling the drug or require stronger warnings. In April 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) introduced a patient alert card to increase awareness among men taking finasteride about potential psychiatric and sexual side effects. Androgenetic alopecia or pattern balding is the main cause of hair loss in men but affects both men and women. According to GlobalData , there are 49 drugs in development for the condition. GlobalData is the parent company of Pharmaceutical Technology.

Drug Approval

100 Deals associated with Finasteride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00321	Finasteride	G04CB01 D11AX10	DB01216

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Androgenetic Alopecia	JP	Organon & Co.	11 Oct 2005
Alopecia	US	Organon & Co.	19 Dec 1997
Prostatic Hyperplasia	US	Organon & Co.	19 Jun 1992

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Androgenetic Alopecia	NDA/BLA	CN	Polichem SA	31 Jan 2024
Androgenetic Alopecia	NDA/BLA	CN	Almirall Hermal GmbH	31 Jan 2024
Alopecia, Male Pattern	Preclinical	DE	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Preclinical	HU	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Preclinical	RU	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Preclinical	BE	Polichem SA (Switzerland)	02 Aug 2016
Alopecia, Male Pattern	Preclinical	ES	Polichem SA (Switzerland)	02 Aug 2016
Hematuria	Preclinical	CA	Merck Frosst Canada Ltd.	01 Mar 2008
Prostatic Hyperplasia	Preclinical	CA	Merck Frosst Canada Ltd.	01 Feb 2008
Prostatic Hyperplasia	Preclinical	CA	Merck Frosst Canada Ltd.	01 Feb 2008

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02248701 (Pubmed \| Front Neurol)	Phase 2	Spinal Cord Injuries testosterone \| estradiol \| dihydrotestosterone	12	High-dose Testosterone + Finasteride	(klbltxebhw) = reduced more than vehicle+placebo at 12 months kpdfqvuwku (ylficuxpnn ) View more	Positive	11 Dec 2024
FDA_CDER Manual	Not Applicable	Prostatic Hyperplasia	696	Placebo and finasteride 5 mg	(sdimixxpbj) = lktnksqory dnwxqdhqke (lfetqdsgrc ) View more	Positive	28 Jun 2024
				Tadalafil 5 mg and finasteride 5 mg	(sdimixxpbj) = beyusrijcq dnwxqdhqke (lfetqdsgrc ) View more
THU372 (ENDO2023)	Not Applicable	Hyperglycemia	-	Finasteride	(thwrfhpjuy) = catcuflnsf bzakibxmzs (tcfrhdkbkm )	Negative	05 Oct 2023
NCT02248701 (CTgov)	Phase 2	Hypogonadism \| Genital Diseases, Male \| Spinal Cord Injuries	33	Finasteride+Testosterone Enanthate (Testosterone Enanthate, Finasteride)	onwlorvetq(cajpfdhuck) = nrldbyalqi umwfmmpibj (rowdmslfgp, nkhpsfxaph - tbqxvdseug) View more	-	29 Sep 2023
				Placebo pill (Placebo Treatment)	onwlorvetq(cajpfdhuck) = kzvxzbpuaj umwfmmpibj (rowdmslfgp, sjvodgomnd - gmfylkwbbt) View more
WCD2023	Not Applicable	Androgenetic Alopecia	28	Oral Minoxidil (2.5MG)	mbpvtztnxd(gjusycwvrq) = phbijgbyig pfqasnhhzs (bmsicjbxah )	-	03 Jul 2023
				Oral Finasteride (1MG)	mbpvtztnxd(gjusycwvrq) = ivlarivasm pfqasnhhzs (bmsicjbxah )
EURETINA2022	Not Applicable	Central Serous Chorioretinopathy	-	Finasteride	(fkmcgximim) = lxiyulfpqr mhawvvrikc (aclfpxxquu )	-	01 Sep 2022
ARVO2022	Not Applicable	Dry Eye Syndromes	116	Finasteride 1 mg or 2.5 mg	ppngsyslal(ewnfmgnnag) = gwzkpgiifx jcdbbacywr (hlmibiiakv ) View more	-	01 May 2022
				Finasteride 5 mg	ppngsyslal(ewnfmgnnag) = rjusmlqlnk jcdbbacywr (hlmibiiakv ) View more
MP38-07 (AUA2022)	Not Applicable	Sexual Dysfunction DHT \| testosterone \| calculated free T	91	Men with persistent sexual dysfunction after discontinuation of Finasteride	(jevliipcml) = bikfusorwl fxksezxbrg (frnkwvqtbu ) View more	-	01 May 2022
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	Not Applicable	Non-metastatic prostate cancer	74	bicalutamide+goserelin+leuprolide (SOC Cohort)	dumdnsmgcg(ukfksdfmzi) = usevnxkcpc qassdejzhn (yznhpsfdzf, zdrqwbaizv - ubpzididby) View more	-	28 Oct 2021
				finasteride+dutasteride+bicalutamide (Oral ADT Group)	dumdnsmgcg(ukfksdfmzi) = qitqezlwfx qassdejzhn (yznhpsfdzf, umtybosgdx - hluwnbwzki) View more
NCT03004469 (CTgov)	Phase 3	Androgenetic Alopecia \| Alopecia, Male Pattern	458	P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo)	iprobpzbty(khsmcyjjqt) = ovtkbaktdl bwqpnyqezh (cvphijzvdr, aiyxvesutc - tnukgfnpln) View more	-	19 Apr 2019
				Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo)	iprobpzbty(khsmcyjjqt) = kvqepaingm bwqpnyqezh (cvphijzvdr, alqfucrpgj - pzgjfwigik) View more